Adjuvant-containing control arms in pivotal quadrivalent human papillomavirus vaccine trials: restoration of previously unpublished methodology
| Autor: | Kyungwan Hong, Peter Doshi, Mark Jones, Florence T. Bourgeois, Larissa Shamseer, O'Mareen Spence, Haeyoung Lee, Tom Jefferson |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Research Report
medicine.medical_specialty Blinding medicine.medical_treatment Control (management) paediatric infectious disease & immunisation 030204 cardiovascular system & hematology Human papillomavirus vaccine 03 medical and health sciences 0302 clinical medicine Informed consent medicine Humans Papillomavirus Vaccines 030212 general & internal medicine Original Research Protocol (science) business.industry General Medicine Family medicine Cohort business Consent Forms Adjuvant |
| Zdroj: | BMJ Evidence-Based Medicine |
| ISSN: | 2515-4478 2515-446X |
| DOI: | 10.1136/bmjebm-2019-111331 |
| Popis: | PurposeTrustworthy reporting of quadrivalent human papillomavirus (HPV) vaccine trials is the foundation for assessing the vaccine’s risks and benefits. However, several pivotal trial publications incompletely reported important methodological details and inaccurately described the formulation that the control arms received. Under the Restoring Invisible and Abandoned Trials initiative (RIAT), we aim to restore the public record regarding the content and rationale of the controls used in the trials.MethodsWe assembled a cohort (five randomised controlled trials) described as placebo-controlled using clinical study reports (CSRs) obtained from the European Medicines Agency. We extracted the content and rationale for the choice of control used in each trial across six data sources: trial publications, register records, CSR synopses, CSR main bodies, protocols and informed consent forms.ResultsAcross data sources, the control was inconsistently reported as ‘placebo’-containing aluminium adjuvant (sometimes with dose information). Amorphous aluminium hydroxyphosphate sulfate (AAHS) was not mentioned in any trial registry entry, but was mentioned in all publications and CSRs. In three of five trials, consent forms described the control as an ‘inactive’ substance. No rationale for the selection of the control was reported in any trial publication, register, consent form, CSR synopsis or protocol. Three trials reported the rationale for choice of control in CSRs: to preserve blinding and assess the safety of HPV virus-like particles as the ‘safety profile of (AAHS) is well characterised’.ConclusionsThe stated rationale of using AAHS control—to characterise the safety of the HPV virus-like particles—lacks clinical relevance. A non-placebo control may have obscured an accurate assessment of safety and the participant consent process of some trials raises ethical concerns.Trial registration numbersNCT00092482,NCT00092521,NCT00092534,NCT00090220,NCT00090285. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|